/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED
STATES/
OTTAWA, ON, July 30, 2020 /CNW Telbec/ - Tetra
Bio-Pharma Inc. ("Tetra" or
the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a leader
in cannabinoid-derived drug discovery and development, is pleased
to announce that the previously announced graduation of the
Corporation's common shares (the "Common Shares") and listed
warrants (the "Warrants") is expected to occur on
August 4, 2020.
The Corporation previously announced on July 15, 2020 that it had received conditional
approval from the Toronto Stock Exchange ("TSX") to graduate
from the TSX-Venture Exchange ("TSX-V"), where the Common
Shares and certain of its Warrants are currently listed, subject to
satisfying certain standard listing requirements.
The graduation is expected to occur on August 4, 2020, and the Common Shares and
Warrants are expected to be listed and commence trading on the TSX
at the opening of markets on same date under the symbols "TBP",
"TBP.WT", "TBP.WT.A" and "TBP.WT.B", respectively. In connection
with such graduation, the Corporation's Common Shares and listed
Warrants will be voluntarily delisted from the TSX-V. The Common
Shares will continue to trade on the OCTQB market under the symbol
"TBPMF".
The Common Shares and Warrants have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the
"U.S. Securities Act") or any U.S. state securities laws and
may not be offered or sold in the United
States absent registration or an applicable exemption from
the registration requirements of the U.S. Securities Act and
applicable U.S. state securities laws.
This press release does not constitute an offer to sell or a
solicitation of any offer to buy the securities in the United States, in any province or
territory of Canada or in any
other jurisdiction. There shall be no sale of the securities in any
jurisdiction in which an offer to sell, a solicitation of an offer
to buy or sale would be unlawful.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP)
(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid based
drug discovery and development with a Health Canada approved, and
FDA reviewed, clinical program aimed at bringing novel prescription
drugs and treatments to patients and their healthcare providers.
The Corporation has several subsidiaries engaged in the development
of an advanced and growing pipeline of Bio Pharmaceuticals, Natural
Health and Veterinary Products containing cannabis and other
medicinal plant-based elements. With patients at the core of what
we do, Tetra Bio-Pharma is focused on providing rigorous scientific
validation and safety data required for inclusion into the existing
bio pharma industry by regulators, physicians and insurance
companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Corporation believes, expects or anticipates
will or may occur in the future (including, without limitation, the
listing of the Common Shares and the listed Warrants on the TSX and
the delisting of the Common Shares and listed Warrants from the
TSX-V) are forward-looking statements. Forward-looking statements
are generally identifiable by use of the words "may", "will",
"should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Corporation's ability
to control or predict, that may cause the actual results of the
Corporation to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Corporation to obtain sufficient financing to execute the
Corporation's business plan; competition; regulation and
anticipated and unanticipated costs and delays, the success of the
Corporation's research and development strategies, including the
success of this product or any other product, the applicability of
the discoveries made therein, the successful and timely completion
and uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Corporation's public disclosure record on file with the relevant
securities regulatory authorities. Although the Corporation has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Corporation does not undertake an obligation to publicly update
such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.
SOURCE Tetra Bio-Pharma Inc.
